Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OxyContin's Planned Epidemiological Study Program

You may also be interested in...



Abuse Reduction Claim In Opioid Label Will Be Difficult To Attain

FDA draft guidance says there is no clear epidemiologic strategy for gathering the data to demonstrate that has reduced abuse; the agency outlines four possible kinds of abuse deterrence claims, three of which can be obtained through pre-market studies.

Pfizer Will Study Oxecta Abuse/Misuse Potential Post-Market

FDA okays the opioid, which contains abuse-resistant components, with labeling about a study that found the drug less likeable than immediate-release oxycodone.

Pfizer Will Study Oxecta Abuse/Misuse Potential Post-Market

FDA okays the opioid, which contains abuse-resistant components, with labeling about a study that found the drug less likeable than immediate-release oxycodone.

Topics

UsernamePublicRestriction

Register

OM004634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel